A comparison was made using EGFR mutation-positive samples (Ex19Del, L858R, and T790M) diluted from approximately 2× LoD to 0.03× LoD, along with an EGFR mutation-negative control, and four panels: 1) sheared cell-line DNA diluted into healthy donor plasma; 2) sheared cell-line DNA diluted into EGFR mutation-negative NSCLC plasma; 3) sheared cell-line DNA diluted into healthy donor whole blood prior to plasma separation; and 4) EGFR mutation-positive plasma diluted in EGFR mutation-negative NSCLC patient plasma samples (reference panel). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.